The latest announcement is out from IM Cannabis Corp ( (TSE:IMCC) ).
IM Cannabis Corp reported significant financial improvements for the fourth quarter and full year 2024, highlighted by a 25% increase in quarterly revenue and a 42% decrease in operating expenses. The company achieved a $0.5M adjusted EBITDA profit in Q4 2024, marking a turnaround from previous losses. The substantial growth in Germany’s revenue by 183% was a key driver, despite a decrease in revenue from Israel due to the cancellation of the Oranim deal. The company’s strategic and operational improvements, including cost management and integration efforts, have positioned it for continued growth in 2025.
More about IM Cannabis Corp
IM Cannabis Corp is an international medical cannabis company, focusing on the production and distribution of medical cannabis products. The company operates primarily in Germany and Israel, with a significant market presence in the medical cannabis industry.
YTD Price Performance: -19.39%
Average Trading Volume: 11,971
Technical Sentiment Signal: Buy
Current Market Cap: $5.3M
Find detailed analytics on IMCC stock on TipRanks’ Stock Analysis page.